Glaxo taps furious demand as US buyers lap up $2.5bn
GlaxoSmithKline this week provided the fix of high grade corporate credit US bond investors have been desperate for all year when it launched a blow-out $2.5bn three tranche global deal, its first ever issue in the dollar market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts